2 results about "Mental retardations" patented technology

New gelatinase inhibitors, processes for their preparation, pharmaceutical compositions comprising them, and their use in therapy and / or prophylaxis of conditions wherein inhibition of gelatinases is useful such as epilepsy, schizophrenia, Alzheimer disease, autism (in particular associated to fragile X syndrome), mental retardation, mood disorders such as bipolar disorders, depression, vascular diseases such as ischemic stroke and atherosclerosis, inflammatory diseases such as multiple sclerosis and rheumatoid arthritis, drug addiction, neuropathic pain, lung diseases such as asthma and chronic obstructive pulmonary disease, cancer and sepsis.

The application provides application of polycyclic polyisoprenyl acyl phloroglucinol compounds (PPAP) of two different skeleton types in preparation of medicines for relieving / treating neurodegenerative diseases. The application belongs to the technical field of medicines. The hyphenrone A provided by the application is a 1,9-cracked polycyclic polyisoprenyl acyl phloroglucinol compound, and the hyphenrone L is a polycyclic polyisoprenyl acyl phloroglucinol compound with a complex ring system formed by intramolecular [4+2] cyclization of a monocyclic polyisoprenyl acyl phloroglucinol compound. The compound hyphenrone A and the compound hyphenrone L both have the activity of enhancing the voltage-gated T-type calcium channel current, and can be used for preparing medicines for treating neurodegenerative diseases, and in particular, can be used for preparing medicines for relieving and / or treating diseases such as spinocerebellar ataxia, Alzheimer's disease and mental retardation syndrome, and have the clinical application value.